Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus.
Friemann
S
S
Department of Internal Medicine, Justus-Liebig-University Giessen, Germany.
Feuring
E
E
Padberg
W
W
Ernst
W
W
D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000517:prevention & control; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology* / Q000502:physiology; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D016559:Tacrolimus / Q000009:adverse effects* / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D007166:Immunosuppressive Agents; D008055:Lipids; D014280:Triglycerides; D016572:Cyclosporine; D002784:Cholesterol; D011239:Prednisolone; D001379:Azathioprine; D016559:Tacrolimus